Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin

Damien R. Ashby,[1,3] Daniel P. Gale,[1,4] Mark Busbridge,[2] Kevin G. Murphy,[3] Neill D. Duncan,[1] Tom D. Cairns,[1] David H. Taube,[1] Stephen R. Bloom,[3] Frederick W.K. Tam,[1] Richard Chapman,[2] Patrick H. Maxwell,[4] and Peter Choi[1]

[1]Imperial College Kidney and Transplant Institute; [2]Department of Clinical Biochemistry, and [3]Department of Investigative Medicine, Hammersmith Hospital, Imperial College London; [4]Division of Medicine, University College London, UK

Citation: Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FWK, Chapman R, Maxwell PH, and Choi P. Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica. 2010;95:505-508. doi: 10.3324/haematol.2009.013136



Online Supplementary Figure S1. Effect of erythropoietin administration on plasma hepcidin. Individual responses to erythropoietin administration at 09:00 on day 2.



Online Supplementary Figure S2. Effect of erythropoietin administration on plasma transferrin saturation. Individual responses to erythropoietin administration at 09:00 on day 2.



Online Supplementary Figure S3. Effect of erythropoietin administration on plasma total iron binding capacity. Individual responses to erythropoietin administration at 09:00 on day 2. 2.



Online Supplementary Figure S4. Effect of erythropoietin administration on plasma iron. Individual responses to erythropoietin administration at 09:00 on day 2.